EXL01 in the Clinic

Evaluating the therapeutic potential of EXL01 in a diversified and complementary set of indications for which F. prausnitzii's signal has been reported.
Learn more about F. praustnizii in Inflammatory Bowel Diseases

EXL01 in Crohn's Disease

A two-part, partially double-blind, randomized phase 1 maintenance trial evaluating EXL01 for the maintenance of steroid-induced remission in patients with mild-to-moderate Crohn’s disease, is currently recruiting.
Learn more about F. praustnizii in Inflammatory Bowel DiseasesLearn more about EXL01 in Crohn's disease

EXL01 in Cancer Immunotherapy

Coming-up in 2023 - Evaluating the potential of EXL01 in combination with Immune Checkpoint Inhibitors in several immuno-oncology indications.
Learn more about F. praustnizii in cancerLearn more about EXL01 in cancer

EXL01 in Infectious Diseases

Ongoing preclinical work. 


EXL02 is a pre-clinical Live Biotherapeutic candidate leveraging the properties of another gut bacteria, with a focus on its ability to activate the AhR-pathway.


EXL03 is a preclinical recombinant protein candidate mimicking the properties of natural enzymes, in particular its ability to activate the Kynurenine pathway.

We would be glad to discuss partnership opportunities with you

Let's team up




Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.